"Rosolov\u00E1, Hana" . "978-80-204-3361-9" . . . . . . . "Jak spr\u00E1vn\u011B l\u00E9\u010Dit pacienta s poruchou lipidov\u00E9ho metabolismu"@cs . . "RIV/00216208:11140/14:10286460" . "1"^^ . "295"^^ . "1"^^ . . "Porucha lipidov\u00E9ho metabolismu (dyslipid\u00E9mie) je nej\u010Dast\u011Bj\u0161\u00ED porucha metabolismu. Dyslipid\u00E9mie p\u0159edstavuj\u00ED riziko pro rozvoj ateroskler\u00F3zy a kardiovaskul\u00E1rn\u00EDch (KV) nemoc\u00ED. Jejich klinick\u00FD v\u00FDznam je ur\u010Den\u00FD intenzitou poruchy a celkov\u00FDm KV rizikem. Dyslipid\u00E9mie vznikaj\u00ED na podklad\u011B interakce genetick\u00E9ho pozad\u00ED a \u017Eivotn\u00EDho stylu. Hlavn\u00EDm smyslem l\u00E9\u010Dby dyslipid\u00E9mi\u00ED je sn\u00ED\u017Een\u00ED rizika \u010Dast\u00FDch chorob, resp. nemocnost a \u00FAmrtnost na KV nemoci. Prim\u00E1rn\u00EDm c\u00EDlem l\u00E9\u010Dby je sn\u00ED\u017Een\u00ED koncentrace LDL-cholesterolu (ch) v krvi. L\u00E9kem 1. volby jsou statiny. P\u0159i nedosa\u017Een\u00ED c\u00EDlov\u00FDch hodnot LDL-ch je mo\u017Eno p\u0159idat ezetimib. Enormn\u011B zv\u00FD\u0161en\u00E1 hodnota triglycerid\u016F (TG) je rizikov\u00E1 pro rozvoj akutn\u00ED pankreatitidy. M\u00EDrn\u011B zv\u00FD\u0161en\u00E1 koncentrace TG je pova\u017Eovan\u00E1 za marker rizika pro vznik ateroskler\u00F3zy a KV nemoc\u00ED a je \u010Dasto spojena s n\u00EDzkou koncentrac\u00ED protektivn\u00EDho HDL-ch (aterogenn\u00ED dyslipid\u00E9mie). Sekund\u00E1rn\u00EDm c\u00EDlem l\u00E9\u010Dby aterogenn\u00ED dyslipid\u00E9mie je hodnota non-HDL-ch nebo po\u010Det v\u0161ech aterogenn\u00EDch \u010D\u00E1stic (apolipoprotein B). Farmakoterapie t\u00E9to dyslipid\u00E9mie nen\u00ED zcela do\u0159e\u0161ena. Zat\u00EDm se doporu\u010Duje kombinovan\u00E1 terapie statinu s fibr\u00E1tem nebo statinu s ezetimibem. V kapitole jsou uvedeny v\u0161echny c\u00EDlov\u00E9 hodnoty LDL-ch, non-HDL-ch a apo-B , kter\u00E9 jsou rozd\u00EDln\u00E9 - podle celkov\u00E9ho KV rizika."@cs . "[3064A12B7B39]" . "I" . "Kardiologie pro intern\u00ED praxi" . . "Dyslipidemias are the most frequent disorder among all metabolic diseases. Dyslipidemias represent risk for atherosclerosis and cardiovascular (CV) disease development. Level of plasma lipids and global CV risk are both determinants of dyslipidemia clinical significance. Pathophysiological background of lipid metabolism disorder depends on an interaction of genetic predisposition and life-style habits. The main sense of dyslipidemia management is to reduce CV morbidity and mortality. The primary aim of dyslipidemia therapyt is to reduce plasma LDL-cholesterol (ch) concentration; statin is the 1-st choice drug. When the recommended LDL-ch level is not achieve, it is possible to add ezetimibe to stati\u00EDn therapy. Enormously elevated triglycerides (TG) level (more than 7 mmol/l) brings very high risk for acute pancreatitis. Moderately elevated TG level (especially in combination with low level of HDL-ch; atherogenic dyslipidemia) is considered as a marker for atherosclerotic CV disease risk. The secondaty aim of dyslipidemia therapy is non-HDL-ch or apolipoprotein B. Pharmacotherapy of atherogenic dyslipidemia is not yet clear; combined therapy with statin and fibrates or statin with ezetimibe are still recommended. All recommended levels of LDL-ch (primary aim), non-HDL-ch and/or apolipoprotein B (secondary aims) according to the global CV risk are presented in this chapter."@en . "RIV/00216208:11140/14:10286460!RIV15-MSM-11140___" . "11140" . . . "combined lipid modifying therapy; statins; atherogenic dyslipidemia; hypercholesterolemia; dyslipidemia treatment"@en . "20"^^ . . "Mlad\u00E1 fronta" . "Edice postgradu\u00E1ln\u00ED medic\u00EDny" . . "What is the right treatment of patients with lipid metabolism disorders?"@en . "Jak spr\u00E1vn\u011B l\u00E9\u010Dit pacienta s poruchou lipidov\u00E9ho metabolismu" . . "Jak spr\u00E1vn\u011B l\u00E9\u010Dit pacienta s poruchou lipidov\u00E9ho metabolismu" . "Jak spr\u00E1vn\u011B l\u00E9\u010Dit pacienta s poruchou lipidov\u00E9ho metabolismu"@cs . "Praha" . "What is the right treatment of patients with lipid metabolism disorders?"@en . "Porucha lipidov\u00E9ho metabolismu (dyslipid\u00E9mie) je nej\u010Dast\u011Bj\u0161\u00ED porucha metabolismu. Dyslipid\u00E9mie p\u0159edstavuj\u00ED riziko pro rozvoj ateroskler\u00F3zy a kardiovaskul\u00E1rn\u00EDch (KV) nemoc\u00ED. Jejich klinick\u00FD v\u00FDznam je ur\u010Den\u00FD intenzitou poruchy a celkov\u00FDm KV rizikem. Dyslipid\u00E9mie vznikaj\u00ED na podklad\u011B interakce genetick\u00E9ho pozad\u00ED a \u017Eivotn\u00EDho stylu. Hlavn\u00EDm smyslem l\u00E9\u010Dby dyslipid\u00E9mi\u00ED je sn\u00ED\u017Een\u00ED rizika \u010Dast\u00FDch chorob, resp. nemocnost a \u00FAmrtnost na KV nemoci. Prim\u00E1rn\u00EDm c\u00EDlem l\u00E9\u010Dby je sn\u00ED\u017Een\u00ED koncentrace LDL-cholesterolu (ch) v krvi. L\u00E9kem 1. volby jsou statiny. P\u0159i nedosa\u017Een\u00ED c\u00EDlov\u00FDch hodnot LDL-ch je mo\u017Eno p\u0159idat ezetimib. Enormn\u011B zv\u00FD\u0161en\u00E1 hodnota triglycerid\u016F (TG) je rizikov\u00E1 pro rozvoj akutn\u00ED pankreatitidy. M\u00EDrn\u011B zv\u00FD\u0161en\u00E1 koncentrace TG je pova\u017Eovan\u00E1 za marker rizika pro vznik ateroskler\u00F3zy a KV nemoc\u00ED a je \u010Dasto spojena s n\u00EDzkou koncentrac\u00ED protektivn\u00EDho HDL-ch (aterogenn\u00ED dyslipid\u00E9mie). Sekund\u00E1rn\u00EDm c\u00EDlem l\u00E9\u010Dby aterogenn\u00ED dyslipid\u00E9mie je hodnota non-HDL-ch nebo po\u010Det v\u0161ech aterogenn\u00EDch \u010D\u00E1stic (apolipoprotein B). Farmakoterapie t\u00E9to dyslipid\u00E9mie nen\u00ED zcela do\u0159e\u0161ena. Zat\u00EDm se doporu\u010Duje kombinovan\u00E1 terapie statinu s fibr\u00E1tem nebo statinu s ezetimibem. V kapitole jsou uvedeny v\u0161echny c\u00EDlov\u00E9 hodnoty LDL-ch, non-HDL-ch a apo-B , kter\u00E9 jsou rozd\u00EDln\u00E9 - podle celkov\u00E9ho KV rizika." . "23164" . . .